Kaiqin Wang

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E.

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E.

Journal: Frontiers in immunology

Published: April 07, 2026

Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice.

Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice.

Journal: Viruses

Published: November 20, 2025

Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model.

Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model.

Journal: Vaccines

Published: June 19, 2024

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.

The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.

Journal: Vaccines

Published: November 28, 2023

Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Journal: Nature communications

Published: November 22, 2023

Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines.

Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines.

Journal: Vaccines

Published: September 10, 2023

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial.

Journal: Frontiers in immunology

Published: June 16, 2023

The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC-MS.

The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC-MS.

Journal: Vaccines

Published: April 14, 2023

Development and validation of a reporter gene assay for bioactivity determination of Anti-CGRP monoclonal antibodies.

Development and validation of a reporter gene assay for bioactivity determination of Anti-CGRP monoclonal antibodies.

Journal: Analytical biochemistry

Published: February 19, 2021

A robust reporter assay for the determination of the bioactivity of IL-4R-targeted therapeutic antibodies.

A robust reporter assay for the determination of the bioactivity of IL-4R-targeted therapeutic antibodies.

Journal: Journal of pharmaceutical and biomedical analysis

Published: August 12, 2020

A reporter gene assay for measuring the bioactivity of anti-LAG-3 therapeutic antibodies.

A reporter gene assay for measuring the bioactivity of anti-LAG-3 therapeutic antibodies.

Journal: Luminescence : the journal of biological and chemical luminescence

Published: April 21, 2020

Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity.

Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity.

Journal: Scientific reports

Published: March 05, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026